scispace - formally typeset
S

Susumu Kobayashi

Researcher at Beth Israel Deaconess Medical Center

Publications -  648
Citations -  23408

Susumu Kobayashi is an academic researcher from Beth Israel Deaconess Medical Center. The author has contributed to research in topics: Total synthesis & Epidermal growth factor receptor. The author has an hindex of 62, co-authored 629 publications receiving 21514 citations. Previous affiliations of Susumu Kobayashi include Chiba University & University of Tokyo.

Papers
More filters
Journal ArticleDOI

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

TL;DR: Nearly 10% of lung adenocarcinomas harbor aberrations that are targetable using the approved multitargeted TKI crizotinib, but co-occurrence of PIK3CA mutation needs to be better evaluated as a modifier of response to TKI therapy.
Journal ArticleDOI

Synthetic analogues and biosynthetic intermediates of bleomycin. Metal-binding, dioxygen interaction, and implication for the role of functional groups in bleomycin action mechanism.

TL;DR: The present results support that the beta-aminoalaninepyrimidine-beta-hydroxyhistidine portion of the bleomycin molecule substantially participates in the Fe(II) and dioxygen interactions.
Journal ArticleDOI

Steryl glucoside is a lipid mediator in stress-responsive signal transduction.

TL;DR: Results strongly suggest that CG acts as a mediator in the early stage of stress responsive signal transduction in fibroblast cells by exposure to exogenously added human major SG, cholesteryl glucoside (CG).
Journal ArticleDOI

Synthesis of 2-O-(3-O-carbamoyl-α-d-mannopyranosyl)-l-gulopyranose: Sugar moiety of antitumor antibiotic bleomycin

TL;DR: In this article, a new route to the disaccharide moiety (2-O-(3-O-carbamoyl-α-d-mannopyranosyl)-l-gulopyranose) of the antitumor agent bleomycin was developed.